About Matt Byron

Matt Byron is a leading transactional advisor with deep experience guiding public and private company clients through their most complex M&A transactions in numerous industries, including life sciences, healthcare, technology and industrials. Matt regularly advises clients on both the buy-side and sell-side of M&A transactions, with market-leading expertise in alternative M&A structures, including asset sales and carve-outs, shareholder spin-out transactions, options to acquire or license, and hybrid licensing and M&A structures. Matt has led recent high-profile M&A transactions for Novo Nordisk, Johnson & Johnson, Gilgamesh Pharmaceuticals, Sanofi, Toast, Qorvo and EMCOR.